➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Moodys
Medtronic
Harvard Business School
Dow

Last Updated: April 21, 2021

DrugPatentWatch Database Preview

DEPAKOTE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Depakote patents expire, and what generic alternatives are available?

Depakote is a drug marketed by Abbvie and Abbott and is included in four NDAs.

The generic ingredient in DEPAKOTE is divalproex sodium. There are eighteen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Depakote

A generic version of DEPAKOTE was approved as divalproex sodium by APOTEX on July 29th, 2008.

  Start Trial

Drug patent expirations by year for DEPAKOTE
Drug Prices for DEPAKOTE

See drug prices for DEPAKOTE

Drug Sales Revenue Trends for DEPAKOTE

See drug sales revenues for DEPAKOTE

Recent Clinical Trials for DEPAKOTE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Virginia Commonwealth UniversityPhase 1/Phase 2
Puma Biotechnology, Inc.Phase 1/Phase 2
Montana State UniversityN/A

See all DEPAKOTE clinical trials

Paragraph IV (Patent) Challenges for DEPAKOTE
Tradename Dosage Ingredient NDA Submissiondate
DEPAKOTE TABLET, DELAYED RELEASE;ORAL divalproex sodium 018723

US Patents and Regulatory Information for DEPAKOTE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie DEPAKOTE divalproex sodium CAPSULE, DELAYED REL PELLETS;ORAL 019680-001 Sep 12, 1989 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No   Start Trial   Start Trial   Start Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-002 Mar 10, 1983 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984 AB RX Yes No   Start Trial   Start Trial   Start Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-001 Mar 10, 1983 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DEPAKOTE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984   Start Trial   Start Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-003 Oct 26, 1984   Start Trial   Start Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-001 Mar 10, 1983   Start Trial   Start Trial
Abbvie DEPAKOTE divalproex sodium CAPSULE, DELAYED REL PELLETS;ORAL 019680-001 Sep 12, 1989   Start Trial   Start Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-001 Mar 10, 1983   Start Trial   Start Trial
Abbvie DEPAKOTE divalproex sodium TABLET, DELAYED RELEASE;ORAL 018723-002 Mar 10, 1983   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Medtronic
Mallinckrodt
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.